Regulus Therapeutics (RGLS) Tops Q3 EPS by 12c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $2.85 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• Playboy to buy back 16.6M shares from Fortress at $1.05 each